Ozempic vs. Retatrutide: One Signal vs. Three Pathways

Every few months a new peptide gets compared to Ozempic like it’s a sports rivalry. Retatrutide is the one drawing the most attention right now, and the comparison is worth making carefully, because the honest version isn’t “which one wins.” It’s a story about two different engineering philosophies solving the same underlying problem.

What Ozempic actually does

Ozempic’s active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 is a gut hormone that signals fullness, slows how quickly food leaves the stomach, and helps regulate insulin release after a meal. Semaglutide mimics that signal and keeps it active for about a week per injection, which is the entire basis of its appetite-suppressing effect.

The evidence behind semaglutide is deep. In the STEP 1 trial, the pivotal study that led to its obesity approval, participants lost an average of 14.9 percent of their body weight over 68 weeks, compared to 2.4 percent on placebo. Eighty-six percent of people on semaglutide lost at least 5 percent of their starting weight (Wilding et al. 989). That’s one hormone signal, amplified and extended, producing results that reshaped an entire category of medicine.

What retatrutide is trying to do differently

Retatrutide starts from the same GLP-1 foundation, then adds two more receptors on top: GIP and glucagon. The idea isn’t that GLP-1 wasn’t good enough. It’s that appetite is only one part of how the body regulates weight, and a molecule that also touches nutrient handling (GIP) and energy expenditure (glucagon) might move more of the underlying biology at once, rather than leaning harder on a single lever.

In its own Phase 3 trial, TRIUMPH-4, participants on the highest dose of retatrutide lost an average of 28.7 percent of body weight, also measured at 68 weeks, the same duration used in the semaglutide STEP 1 data (Eli Lilly, TRIUMPH-4 announcement).

Why you can’t just line those two numbers up

Here’s where most social media comparisons get sloppy. STEP 1 and TRIUMPH-4 are two completely different trials, run years apart, with different enrollment criteria, different participant populations, and different investigators. Comparing their topline numbers side by side feels like a head-to-head result. It isn’t one. Cross-trial comparisons can point toward an interesting question, but they can’t answer it, because none of the dozens of variables that differ between two separate studies are being controlled for.

Side effects tell a similar story to the topline numbers. They’re not directly comparable point for point, but both compounds cluster around the same category of adverse events. Semaglutide’s most common side effects are nausea, diarrhea, and vomiting, all more frequent than placebo. Retatrutide’s Phase 2 and Phase 3 data report the same categories as its dominant adverse events, with GI intolerance the leading reason participants adjust dosing in both drug classes. Adding a third receptor didn’t introduce a new category of risk. It intensified the same one the entire GLP-1 class already carries.

The trial that would actually answer the bigger question, a real head-to-head between semaglutide and retatrutide in the same population under the same conditions, doesn’t exist yet. The closest thing running is TRIUMPH-5, an active-comparator trial still underway. Until results like that are published, the honest answer to “which one works better” is that nobody has actually tested it directly.

The real comparison worth making

What’s genuinely interesting here isn’t a leaderboard. It’s the mechanism design itself. Semaglutide proved that amplifying a single metabolic signal could produce clinically meaningful, durable weight loss and reshape how obesity gets treated. Retatrutide is testing whether coordinating three signals instead of one produces something categorically different, not just a bigger number on the same curve. That’s a real scientific question, and it’s one Phase 3 data is still in the process of answering, not one that’s already settled.

Retatrutide remains investigational and is not approved by the FDA or any other regulator as of this writing. Semaglutide (Ozempic, Wegovy) is FDA-approved for its studied indications. Nothing here should be read as a recommendation for either compound, and neither drug’s approved or investigational status changes based on how compelling its mechanism story is.

References

Eli Lilly and Company. TRIUMPH-4 Phase 3 trial announcement. Press release, December 2025.

Jastreboff, Ania M., et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial.” New England Journal of Medicine, vol. 389, no. 6, 2023, pp. 514-526.

Wilding, John P. H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, vol. 384, no. 11, 2021, pp. 989-1002.